GPC3 (Glypican 3)

MUC5AC/p53 immunohistochemistry is highly effective in identifying high-risk lesions. Enteroblastic differentiation is relatively common and is associated with lymphovascular invasion. These findings support the use of targeted immunohistochemistry for accurately diagnosing and managing this vulnerable and understudied age group.

P1, N=50, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027

Paclitaxel-carboplatin chemotherapy was commenced with dose modifications for hepatotoxicity, complicated by infusion reactions, mild neuropathy, and mucositis. This case underlines the extreme morphological and molecular heterogeneity of hepatic carcinosarcomas, the rapid progression despite surgery, and the limited systemic treatment options available for such rare tumours.

In summary, endometrial carcinomas with a somatically derived yolk sac tumor component are highly aggressive, predominantly p53-abnormal, with smaller subsets classified as MMRd or NSMP. Recognition of the YST component is crucial, and biomarker profiling may reveal therapeutic targets.

[68Ga]Ga-aGPC3-Fab demonstrated a favorable safety profile and enabled effective visualization of GPC3-positive lesions. It may serve as a complementary approach to conventional imaging to improve the diagnostic accuracy of HCC.

The patient was started on capecitabine and oxaliplatin in addition to trastuzumab with subsequent clinical and radiological improvement. Unresectable, metastatic HER2 positive conventional adenocarcinoma is being managed using platinum-fluoropyrimidine doublet therapy with anti-HER2 monoclonal antibody trastuzumab. This case report calls for aggressive IHC staining for prompt diagnosis where necessary as well as proper guidelines for management.

Biodistribution analysis further revealed preferential tumor accumulation (~1.3% injected dose per gram) with minimal radioactivity in non-target organs. Collectively, these findings demonstrate the feasibility and therapeutic potential of 131I-GPC3 as a targeted theranostic radiopharmaceutical for HCC and other GPC3-expressing malignancies.

Activated CD24 promoted HCC formation through programmed death-ligand 1 signaling and could be a valuable biomarker for monitoring chronic liver disease malignancy.

This study demonstrated that GPC3 CAR-T. TROP2 BiTE was a potent therapy for LUSC and provided a strategy for overcoming the antigen heterogeneity in solid tumors.

P=N/A, N=14, Not yet recruiting, Beijing Gaobo Hospital; Beijing Gaobo Hospital

Both matrices under -70 °C storage effectively discriminated HCC from non-HCC cases, although serum demonstrated a significantly better diagnostic performance (AUROC: 0.836, 95% CI: 0.749-0.902 vs. 0.772, 95% CI: 0.677-0.850; p = 0.013). Although plasma offers operational convenience and higher baseline GPC3 levels, serum provides both greater stability and superior diagnostic accuracy under frozen conditions, thus supporting its use as the preferred specimen matrix in clinical and research applications.